Friday 6 November 2026 Export TEVA’s income statement to Excel — free account

Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.

Revenue: −1.90%
EPS: −47.2%
Free cash flow: −30.3%
Total debt: −0.43%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

42.40 0.62 +1.48%

Follow TEVA

Alert me

Market cap: $48.7B
P/E: 92.6×
Fwd P/E: 30.7×
Dividend yield: —
F-score: 8/9
Altman Z: 0.79
Beneish M: −2.35
Dividend safety: 52/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Teva Pharmaceutical Industries Ltd. 10-Q filed Jul 29, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Jul 29, 2026 · accepted 4:02 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 30, 2025: 40 added · 49 removed · 152 modified; 48 with only figures updated; 8 moved without change

Teva Pharmaceutical Industries Ltd. 10-Q filed Jul 29, 2026

What changed

Stockrow Weekly